Moderna gets Autolus targeting tech via licensing deal; Atai reports PhI data for kratom-based therapy
12 Oct 2022
mRNA
A year after Autolus Therapeutics got itself a partner in Moderna via a licensing deal, Moderna is exercising its option to acquire the biotech’s proprietary binders.
The London-based Autolus revealed the option Wednesday morning, saying that the mRNA giant has exercised its option to in-license for an undisclosed I/O target. The original agreement between the two companies was reached back in August 2021, which gave Moderna the option to license Autolus’ tech for up to four immune-oncology targets.
Autolus now has received the exercise payment and remains up to receiving milestone payments and royalties. Shares of
$AUTL
initially went up 15% after the announcement.
Autolus CSO Martin Pule said via a statement that the collaboration with Moderna has been productive, calling it good to see the partnership move forward.
The Peter Thiel-backed startup atai is reporting optimistic data for its OUD (opioid use disorder) candidate.
The biotech reported that drug candidate KUR-101, an oral formulation of a deuterated key component of the kratom plant called mitragynine, showed safety data and that it was well-tolerated in patients. In the single ascending dose portion of the trial, no severe or serious adverse events were reported.
However, efficacy data compared to standard-of-care drugs such as naltrexone and methadone is still in the clinic. Those data are expected by end of the year, which would compare a single dose of KUR-101 to a dose of oxycodone or placebo.
CEO Chad Beyer of atai subsidiary Kures, which is leading the KUR-101 program, said that it’s pleased with the results of the trial.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.